Craig Cruickshank

2Seventybio has announced a definitive merger agreement under which Bristol Myers Squibb (BMS) will acquire the company in an all-cash transaction for a total equity value of approximately US$ 286 million. The transaction has been approved by both companies and is expected to close in Q2 of this year. 2Seventybio

Through the acquisition Jazz Pharmaceuticals gains access to dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma in children and young adults. The transaction has been approved by both companies and is expected to close in Q2 of this year. The acquisition sees Jazz Pharmaceuticals gain